Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 147Carcinoma, Renal Cell 37Parkinson Disease 4, Autosomal Dominant Lewy Body 31Neoplasms 28Cholangiocarcinoma 26Endometrial Neoplasms 19Thyroid Neoplasms 17Liver Neoplasms 17Melanoma 15Stomach Neoplasms 13Carcinoma, Non-Small-Cell Lung 13Biliary Tract Neoplasms 13Recurrence 9Neoplasm Metastasis 9Squamous Cell Carcinoma of Head and Neck 8Ovarian Neoplasms 8Breast Neoplasms 8Uterine Cervical Neoplasms 7Triple Negative Breast Neoplasms 5Thyroid Carcinoma, Anaplastic 5Small Cell Lung Carcinoma 5Neuroendocrine Tumors 5Esophageal Squamous Cell Carcinoma 5Colorectal Neoplasms 5Pancreatic Neoplasms 4Kidney Neoplasms 4Carcinoma, Transitional Cell 4Carcinoma 4Adenocarcinoma 4Thyroid Cancer, Papillary 3

Interventions

pembrolizumab 1lenvatinib 1brivanib 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Hepatocellular Carcinoma (HCC) × lenvatinib × Clear all
NCT07282509 2025-12-15

Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 1/2 Not yet recruiting
116 enrolled
Gastrointestinal

Advanced Hepatocellular Carcinoma (HCC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡